Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1985 Jul;28(1):55–57. doi: 10.1128/aac.28.1.55

Assessment of serum bactericidal activity after administration of cefoperazone, cefotaxime, ceftizoxime, and moxalactam to healthy subjects.

S L Barriere, D C Ozasa, J Mordenti
PMCID: PMC176309  PMID: 3929680

Abstract

Bactericidal activity in serum produced after administration of 1-g intravenous doses of cefoperazone, cefotaxime, ceftizoxime, and moxalactam was ascertained in six healthy subjects. The assay organisms were a strain of Staphylococcus aureus which was moderately susceptible to the drugs (MBC, 2 to 8 micrograms/ml) and an isolate of Escherichia coli which was highly susceptible (MBC, 0.08 to 0.3 microgram/ml). Drug concentrations and bactericidal titers were measured from samples taken for up to 12 h after the dose. No bactericidal activity against the S. aureus strain was found at 4 to 6 h and beyond for any of the drugs. Ranking of the in vivo bactericidal activity of the drugs was cefoperazone = cefotaxime greater than ceftizoxime = moxalactam. Against the E. coli isolate, bactericidal activity was present for 8 h for cefotaxime, and for 12 h for the other drugs. Ranking of the drugs in terms of extent and duration of in vivo bactericidal activity versus E. coli was moxalactam = ceftizoxime greater than cefoperazone greater than cefotaxime. After administration of 1-g doses of these new beta-lactams, bactericidal activity in serum was maintained for 12 h against highly susceptible bacteria. More frequent (6 to 8 h) or higher (greater than or equal to 2 g) dosing appears to be necessary to achieve prolonged serum bactericidal activity against less susceptible isolates (MBC, greater than or equal to 2 to 8 micrograms/ml).

Full text

PDF
55

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barriere S. L., Flaherty J. F. Third-generation cephalosporins: a critical evaluation. Clin Pharm. 1984 Jul-Aug;3(4):351–373. [PubMed] [Google Scholar]
  2. Fass R. J. Comparative in vitro activities of third-generation cephalosporins. Arch Intern Med. 1983 Sep;143(9):1743–1745. [PubMed] [Google Scholar]
  3. Gerber A. U., Craig W. A., Brugger H. P., Feller C., Vastola A. P., Brandel J. Impact of dosing intervals on activity of gentamicin and ticarcillin against Pseudomonas aeruginosa in granulocytopenic mice. J Infect Dis. 1983 May;147(5):910–917. doi: 10.1093/infdis/147.5.910. [DOI] [PubMed] [Google Scholar]
  4. Jones R. N., Barry A. L., Thornsberry C. Antimicrobial activity of desacetylcefotaxime alone and in combination with cefotaxime: evidence of synergy. Rev Infect Dis. 1982 Sep-Oct;4 (Suppl):S366–S373. doi: 10.1093/clinids/4.supplement_2.s366. [DOI] [PubMed] [Google Scholar]
  5. Klastersky J., Daneau D., Swings G., Weerts D. Antibacterial activity in serum and urine as a therapeutic guide in bacterial infections. J Infect Dis. 1974 Feb;129(2):187–193. doi: 10.1093/infdis/129.2.187. [DOI] [PubMed] [Google Scholar]
  6. Kowalsky S. F., Echols R. M., Venezia A. R., Andrews E. A. Pharmacokinetics of ceftizoxime in subjects with various degrees of renal function. Antimicrob Agents Chemother. 1983 Aug;24(2):151–155. doi: 10.1128/aac.24.2.151. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. MacArthur R. D., Jackson G. G. An evaluation of the use of statistical methodology in the Journal of Infectious Diseases. J Infect Dis. 1984 Mar;149(3):349–354. doi: 10.1093/infdis/149.3.349. [DOI] [PubMed] [Google Scholar]
  8. Neu H. C. The new beta-lactamase-stable cephalosporins. Ann Intern Med. 1982 Sep;97(3):408–419. doi: 10.7326/0003-4819-97-3-408. [DOI] [PubMed] [Google Scholar]
  9. Reller L. B., Stratton C. W. Serum dilution test for bactericidal activity. II. Standardization and correlation with antimicrobial assays and susceptibility tests. J Infect Dis. 1977 Aug;136(2):196–204. doi: 10.1093/infdis/136.2.196. [DOI] [PubMed] [Google Scholar]
  10. Sculier J. P., Klastersky J. Significance of serum bactericidal activity in gram-negative bacillary bacteremia in patients with and without granulocytopenia. Am J Med. 1984 Mar;76(3):429–435. doi: 10.1016/0002-9343(84)90662-4. [DOI] [PubMed] [Google Scholar]
  11. Standiford H. C., Drusano G. L., Fitzpatrick B., Tatem B., Schimpff S. C. Bactericidal activity of ceftazidime in serum compared with that of ticarcillin combined with amikacin. Antimicrob Agents Chemother. 1984 Sep;26(3):339–342. doi: 10.1128/aac.26.3.339. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Standiford H. C., Drusano G. L., McNamee W. B., Tatem B., Ryan P. A., Schimpff S. C. Comparative pharmacokinetics of moxalactam, cefoperazone, and cefotaxime in normal volunteers. Rev Infect Dis. 1982 Nov-Dec;4 (Suppl):S585–S594. doi: 10.1093/clinids/4.supplement_3.s585. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES